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Fructose is a highly lipogenic dietary nutrient that has been implicated in the pathogenesis of hyperlipidemia
and insulin resistance. In this issue, Nagai et al. (2009) provide in vivo evidence that pinpoints transcriptional
coactivator PGC-1b as a key factor in mediating the metabolic response to fructose intake.
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PreviewsThe consumption of the Westernized diet
is a major factor that contributes to the
global epidemic of the metabolic
syndrome and type 2 diabetes. Dietary
intake of fructose, which is commonly
derived from sweeteners based on
sucrose or high-fructose corn syrup, was
estimated to increase by 20%–40% over
the last three decades (Havel, 2005).
Numerous studies in humans and animal
models have implicated fructose in the
pathogenesis of insulin resistance and
dyslipidemia, in particular hypertriglyceri-
demia (Havel, 2005; Rutledge and Adeli,
2007). Fructose is absorbed by entero-
cytes through GLUT5, a fructose-specific
hexose transporter, and reaches the liver
through the portal circulation. Compared
to glucose, fructose is more potent in
the stimulation of de novo hepatic lipo-
genesis and VLDL secretion (Hellerstein
et al., 1996), which subsequently impact
on systemic energy metabolism and
insulin sensitivity. The exact molecular
pathway that mediates the effects of fruc-
tose on hepatic lipogenesis and insulin
resistance remains unclear. A new study
in this issue (Nagai et al. 2009) revealed
the transcriptional coactivator PPARg
coactivator-1b (PGC-1b) as a missing
link between fructose intake and meta-
bolic disorders.
The lipogenic activity of fructose is
achieved through its effects on the meta-
bolic flux as well as the induction of a
genetic program that supports lipogen-
esis. In the liver, fructose enters the glyco-
lytic pathway downstream of phospho-
fructokinase, a rate-limiting enzyme in
glycolysis, and generates carbons for
the synthesis of fatty acids and triglycer-
ides. As a result, high levels of fructose
intake provide an essentially unregulated
source of acetyl-CoA for hepatic lipogen-
esis. On the other hand, fructose intake
also activates the expression of lipogenicgenes (Nagai et al., 2002), which involves
the induction of sterol regulatory element
binding proteins (SREBP), particularly
SREBP1c, a major transcriptional regu-
lator of lipogenic gene expression (Horton
et al., 2002).
The PGC-1 family of transcriptional
coactivators regulates glucose, lipid, and
mitochondrial oxidative metabolism in
response to nutritional and hormonal
signals (Finck and Kelly, 2006; Lin et al.,
2005a). These coactivators physically
interact with selective transcription
factors as well as cofactors and induce
the transcription of target genes through
remodeling of local chromatin structure.
A case in point is PGC-1b, which coordi-
nates hepatic lipogenesis and lipoprotein
metabolism through coactivating several
transcription factors, including SREBPs,
the liver X receptor (LXR), and forkhead
transcription factor Foxa2 (Lin et al.,
2005b; Wolfrum and Stoffel, 2006). The
expression of PGC-1b in the liver is
induced in response to dietary saturated
fats. Further, adenoviral-mediated ex-
pression of PGC-1b in the liver induces
triglyceride synthesis and VLDL secretion,
leading to hypertriglyceridemia in trans-
duced rats. These effects of PGC-1b on
lipid metabolism are reminiscent of the
metabolic consequences of high-fructose
feeding. Using an antisense oligonucleo-
tide (ASO) strategy, Nagai et al. (2009)
established an important role for PGC-1b
in the pathogenesis of fructose-induced
insulin resistance.
ASO treatments appear to achieve effi-
cient knockdown of endogenous PGC-1b
expression in the liver and white adipose
tissue, but not in soleus and brown
adipose tissue. A partial deficiency of
PGC-1b in these lipogenic tissues makes
it possible to assess the role of this
coactivator inmediating fructose-induced
lipogenesis and insulin resistance. AsCell Metabolisexpected, feeding rats with a high-fruc-
tose diet leads to hypertriglyceridemia,
increased epididymal fat mass, as well
as significant hepatic steatosis, all of
which are characteristics of enhanced
lipogenesis. This dysregulation of lipid
homeostasis is accompanied by insulin
resistance, as evidenced by reduced
whole-body glucose metabolism and
elevated hepatic glucose production.
PGC-1b ASO treatments result in signifi-
cant improvement of metabolic profile,
effectively sparing the treatment group
from the deleterious effects of high-fruc-
tose feeding. Previous studies have
demonstrated that PGC-1b is an impor-
tant regulator of hepatic lipogenesis and
VLDL secretion in response to short-
term high-fat feeding (Lin et al., 2005b).
While PGC-1b ASO appears to also
decrease fasting plasma glucose and
insulin levels in the context of high-fat
feeding, it has modest effects on hepatic
glucose production and whole-body
glucose utilization. These findings place
PGC-1b at a unique regulatory point that
is apparently required for mediating the
adverse metabolic effects of dietary fruc-
tose, but not dietary fats.
Parallel to the improvement of meta-
bolic parameters, PGC-1b ASO sup-
presses the lipogenic response to high-
fructose feeding in the liver. The induction
of SREBP1a, SREBP1c, and fatty acid
synthase by fructose is attenuated in
rats receiving PGC-1b ASO treatments.
Since LXR and SREBP1 regulate the tran-
scription of SREBP1c itself, Nagai et al.
used chromatin immunoprecipitation
(chIP) to demonstrate that the occupancy
of these two transcription factors on the
SREBP1c promoter is reduced when
PGC-1b is knocked down. It is likely that
PGC-1b knockdown reduces the tran-
scriptional activity of LXR and SREBP1,
resulting in repressive chromatinm 9, March 4, 2009 ª2009 Elsevier Inc. 215
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Previewsenvironment on the SREBP1c promoter
and decreased recruitment of these
factors to their respective binding sites.
Additional chIP experiments using anti-
bodies against PGC-1b and various
histone marks should provide further
insights into this pathway. The findings
are somewhat paradoxical as PGC-1b
does not appear to directly regulate the
expression of SREBP1c in previous gain-
of-function studies (Lin et al., 2005b). This
dilemma raises the possibility that the
inhibition of SREBP1 expression by PGC-
1b ASO could be secondary to altered
hormonalmilieu, particularly insulin,which
is a potent activator of SREBP1c gene
expression.
It is remarkable that PGC-1b ASO dras-
tically enhances glucose uptake by white
adipose tissue when the rats were fed
a fructose-rich diet. This appears to be
an important contributor to the improve-
ment in whole-body glucose utilization.
Interestingly, the total levels as well as
the membrane pool of GLUT4 protein
are significantly elevated in the white fat
following PGC-1b ASO treatments. While
the exact molecular mechanisms are
currently unknown, these surprising find-216 Cell Metabolism 9, March 4, 2009 ª200ings could potentially reveal a novel link
between PGC-1b and the regulation of
GLUT4 protein turnover and/or transla-
tion.
An unresolved issue is how PGC-1b
interacts with dietary fructose to bring
about the desirable responses. In this
regard, PGC-1b knockdown apparently
causes hepatic insulin resistance in the
rats fed a regular chow. A plausible expla-
nation for these findings is that PGC-1b
ASO impairs mitochondrial function in
the liver, in particular the expression of
genes involved in fatty acid b-oxidation,
and causes hepatic insulin resistance.
However, similar decreases were also
observed in PGC-1b ASO-treated rats
fed a high-fructose diet. This discrepancy
raises an intriguing possibility that PGC-
1bmay serve as a nodal point that modu-
lates the interaction between dietary
nutrients and the metabolic regulatory
programs. The findings by Nagai et al.
support the emerging role of gene/envi-
ronment interaction in modulating the
metabolic phenotype and disease patho-
genesis. Thus, perturbations of the same
regulatory motif may produce vastly
different metabolic responses, depending9 Elsevier Inc.on the specific combinations of dietary
nutrients.
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